Search

Your search for "xphy" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Proprietary COVID-19 PCR Test COVID-ID Lab Launch Deemed a Success

September 8, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that the market launch of its 25-minute COVID-19 PCR Test COVID-ID Lab has been a success. The company unveiled the project at test centers in Berlin, and XPhyto reports the successfully optimization of operational procedures and […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Registers First Oral Disease Biosensor for Commercialization

August 30, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has registered its first biosensor test in oral inflammation with German authorities. The company registered the easy, at-home, self-check test with the assistance of its partner and acquisition target, 3a-diagnostics GmbH (“3a”). The biosensor […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in “Forbes” Article Discussing Mescaline

August 13, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, was featured in an article titled “Is Mescaline a Key Component in the Future of Medicine? XPhyto Aims to Find Out.” The article notes that mescaline (3,4,5-trimethoxyphenethylamine), the magical alkaloid found in the peyote cactus and similar […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Acquisition Target Identifies Breakthrough COVID-19 Detection Biosensor Candidates

July 28, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, today announced that its acquisition target, 3a-diagnostics GmbH (“3a”), has identified the first saliva activated “in-mouth” biosensor candidates for the detection of a COVID-19 infection. According to the update, the enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Definitive Agreement to Acquire 3a-Diagnostics

July 20, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, has signed a definitive agreement to acquire its exclusive diagnostics development partner 3a-diagnostics GmbH, Frickenhausen, Germany. Per the terms of the definitive agreement, XPhyto will acquire all outstanding shares of 3a for EUR 400,000, to be paid immediately, and EUR 3.5 million, to […]

News Articles

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

July 19, 2021

XPhyto partners with AGORA t to grow its brand and overall market share The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 AGORA is known for its online marketing, conferences, broadcasting […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Covid-ID Lab Filling Existing Market Gap

July 13, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced that its distribution, storage and logistics partner, Max Pharma GmbH, began selling and delivering its 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) in Germany on May 25. The company is likely to benefit from the country’s regulatory requirements and the government’s […]

News Articles

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy

July 12, 2021

XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes XPhyto plans to capitalize on the rapid test market, projected to reach […]

News Articles

XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track

June 30, 2021

XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule” The program, which started in early 2021, is slated for completion in late Q3 2021 The first initial production batches were completed successfully, marking a significant milestone for the program Mescaline will form a critical component in XPhyto’s psychedelic medicine program […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Finalizes Supply Agreement with Two German Companies for COVID-19 PCR Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has inked a master supply agreement with two German diagnostics, testing, and medical logistics companies: Beovita GmbH & Co. KG and Tackleberries GmbH. The two companies run 10 COVID-19 test centers in Berlin. The supply agreement outlines […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Advancing Rotigotine Development Program for Parkinson’s

June 22, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced its drug formulation and development, conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH, are on schedule and continue to expand in scope. A recent article reads, “A Q1 trial announced in January 2021 and focusing on a […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Latest Episode of Bell2Bell Podcast

June 17, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, was featured in the Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director Hugh Rogers joined the latest episode to offer an operational update and discuss the company’s […]

Press Releases

InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Hugh Rogers, CEO of XPhyto Therapeutics Corp.

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of an exclusive The Bell2Bell Podcast interview with Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT). During […]

News Articles

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commences Sale of Rapid COVID-19 RT-PCR Test Kits in Germany Amid Potential Surge in Demand

June 15, 2021

XPhyto’s distribution, storage, and logistics partner, Max Pharma GmbH, began the sale and delivery of its rapid test kits (Covid-ID Labs) in Germany on May 25 Max Pharma will sell Covid-ID Labs at volume-dependent pricing comparable to other COVID-19 PCR test products on the market The announcement comes as Germany reopens, meaning XPhyto is likely […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Looks to Focus Expertise on Psychedelic Drug Formulation as Manufacturing Programs Advance

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community. The audio press release discusses […]

Press Releases

XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies

VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) — via InvestorWire — XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update on Timely Progression of Psychedelic Medicine Program

June 8, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that its GMP mescaline synthesis program is on schedule with the completion of initial production batches. According to the update, the industrial-scale manufacture of pharmaceutical-grade psychedelic compounds, including mescaline and psilocybin, is an important part of XPhyto’s psychedelic medicine program and will provide a foundation […]

News Articles

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Beginning 2021 Strong with New Drugs and Life Sciences Advancements

June 2, 2021

Promising results have been recorded in the first pilot study of a Rotigotine skin patch for Parkinson’s patients Wholly owned subsidiary Vektor is reaching a major milestone in the development of Rotigotine with the potential for a pivotal human trial The company is planning the construction of a new lab and manufacturing space up to […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Potential Expansion of ‘Covid-ID Lab’

May 28, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently received the CE-IVD approval (European certification) of its 25-minute COVID-19 RT-PCR test kits (“Covid-ID Lab”). The approval facilitated initial sale and distribution of the Covid-ID Lab in Germany and, later, other parts of Europe, the Middle East and North America. The company […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Proprietary Covid-ID Lab to Launch in Germany

May 20, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that Marx Pharma GmbH, the company’s distribution, storage and logistics partner, is launching Covid-ID Lab, XPhyto’s 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system in Germany; the product will launch on May 25. The announcement noted that the […]

News Articles

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Targets Potential Expansion of Rapid COVID-19 Test Kit Distribution with Delivery of 2,000 Units to Israel

May 18, 2021

XPhyto recently delivered 2,000 of its rapid Covid-ID Lab test kits to an established Israeli distributor for clinical evaluation by the Ministry of Health The delivery, which marks entry into the Middle East, follows the approval of the test kits in Europe In an earlier interview, CEO Hugh Rogers had noted that XPhyto was looking […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Focuses ‘Covid-ID Lab’ Commercialization Strategy Initially on German Market

May 14, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its entry into the agreement with a full-fledged German pharmaceutical wholesaler and service provider. Under the agreement, the German partner […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Releases Business, Drug-Development Status

May 13, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry,released an update on its 2021 drug formulation programs, noting that the programs are advancing on schedule and expanding in scope. The company’s Rotigotine transdermal human pilot study was successfully completed in March and the program now advancing […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) CEO Talks Business in Two Video Interviews

May 11, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) director and CEO Hugh Rogers was a featured guest on two different video interviews. In both interviews, Rogers shared key information and updates about XPhyto, a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. During his InvestorIntel interview with host Peter […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Launches ‘Covid-ID Lab’ POC Pilot Project in Germany

May 7, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its commencement of a pilot project with its rapid COVID-19 PCR test (“Covid-ID Lab”) in a point-of-care (“POC”) setting in Germany. Covid-ID Lab was recently approved in Europe and offers the accuracy of a PCR test in only 25 minutes. Validated work flows, including mobile […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured on Gamechangers LIVE

May 6, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in a recent episode of Gamechangers LIVE, a podcast series that shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. XPhyto Therapeutics’ CEO and Director, […]

Press Releases

InvestorBrandNetwork Announces Gamechangers LIVE Interview with XPhyto Therapeutics Corp. CEO and Director Hugh Rogers

LOS ANGELES, May 06, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. (CSE: XPHY) (OTC:XPHYF), recently appeared on Gamechangers LIVE, a podcast series putting a spotlight on individuals who are gamechangers in their fields and […]

News Articles

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Distribution Agreement for Rapid COVID-19 Test Kits; Expands Commercial Leadership Team in Anticipation of Strong, Sustainable Sales 

May 4, 2021

XPhyto Therapeutics Corp. recently announced it has entered into a distribution, storage and logistics agreement with a German distributor with an established network throughout Germany Germany holds promise due to regulations requiring mandatory weekly testing for its citizens; this has the possibility of ramping up sales Anticipating the increase in sales and distribution, XPhyto expanded […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Significant Market Opportunity

May 3, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, raised eyebrows when it announced that XPhyto Laboratories Inc., its Alberta subsidiary, added mescaline production to its psychedelic medicine development programs earlier this year (https://ibn.fm/cHwJi). Mescaline has begun attracting legislative attention, much like was the case with cannabis, which gained widening legalization as state […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Pursues Market Access in Israel for ‘Covid-ID Lab’

April 28, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that it has delivered 2,000 of its rapid 25-minute PCR tests (“Covid-ID Lab”) to an established medical distributor in Israel for clinical evaluation of Covid-ID Lab for the purpose of commercial regulatory approval and potential product distribution. According to the update, the Israeli distributor markets […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Achieves Critical Step Toward Commercial Sales of ‘Covid-ID Lab’

April 21, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its entry into an agreement with an established German pharmaceutical wholesaler and service provider for the distribution, storage and logistics of XPhyto’s diagnostic products in Germany. According to the update, the agreement secures XPhyto a full-service distribution partner for its 25-minute SARS-CoV-2 (COVID-19) RT-PCR test […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Appointment of New Global Positions

April 20, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has appointed two new positions at XP Diagnostics GmbH, its wholly owned German subsidiary. Wolfgang Probst will serve as the company’s new chief operations officer and Manfred Buchberger will be the new head […]

News Articles

Largely Untapped Market for Hallucinogenic Draws Attention of Researchers at XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

April 16, 2021

XPhyto Therapeutics Corp., a life sciences technology accelerator, is looking for ways to turn promising psychedelics into therapeutic pharmaceutical drugs, and recently added mescaline to its study profile Mescaline is illegal under U.S. federal law, but some state-centric efforts to legalize or decriminalize the hallucinogenic have launched in a manner similar to the populace effort […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) ‘Covid-ID Lab’ Combines Speed of Rapid Screening with Accuracy of PCR Diagnostic

April 15, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, is set to launch a solution for improving detection of the virus responsible for the worldwide pandemic. The company recently announced European regulatory approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. Known as “Covid-ID Lab,” the system is a commercial in-vitro diagnostic […]

News Articles

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Files First Order for Rapid COVID Test Kits Amid European Regulatory Approval

April 12, 2021

Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partner XPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 […]

News Articles

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commercialization Team Set to Launch Rapid POC COVID Test Solution

April 8, 2021

Bioscience technology accelerator XPhyto Therapeutics Corp. is working with development partner 3a-diagnostics GmbH to roll out its pandemic-related virus diagnostic tool for the European market planned in April The test solution, dubbed “Covid-ID Lab,” received European regulatory approval last month XPhyto’s product is designed to be portable and rapid in its response time to help […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in NetworkNewsAudio Broadcast

March 29, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, this morning announced that it was featured in a NetworkNewsAudio production highlighting the company’s recent news that it has received European approval for its SARS-CoV-2 (COVID-19) RT-PCR test system (Covid-ID Lab). […]

Press Releases

XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Recent European Approval of 25-Minute COVID-19 PCR Test

VANCOUVER, British Columbia, March 29, 2021 (GLOBE NEWSWIRE) — via InvestorWire — XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Working to Expand Test Portfolio

March 24, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which recently received European approval for its COVID-19 rapid and portable test system, has set out to increase its portfolio of tests for different diseases to help fight the current and potential pandemics. XPhyto has partnered with Germany’s 3a-diagnostics GmbH for this, according to an article on […]

InvestorNewsBreaks

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Receives European Approval for 25 Minute COVID-19 PCR Test

March 18, 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT),a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, along with its German diagnostics development partner, 3a-diagnostics GmbH (“3a”), has received European approval of its point-of-care SARS-CoV-2 RT-PCR test system, called Covid-ID Lab. Covid-ID Lab is now registered as a commercial in vitro […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).